Biologic Therapy for Osteoarthritis in Seattle, WA

What I’d check before adding osteoarthritis biologic therapy here

Seattle is a city of 500k–1M (749,256 Census). CDC PLACES (2023, crude) estimates 6.1% of adults in Seattle have diagnosed diabetes — 5.9 points below the U.S. 12% figure. Adult arthritis here is 17% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Keep 361 tissue, autologous PRP, and skin substitutes on different tickets. We onboard against that split — then ship.

Cash PRP and Medicare CTPs in the same hallway

• Adult arthritis here is 17% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. 6.1% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. PRP is autologous and not a 361 allograft, but “patient prefers regenerative” is still not medical necessity in Washington.
• AHR’s BRFSS diabetes range (Colorado 8.4% to West Virginia 18.4%) is state-level, not city-level. We will not invent a Seattle-specific diabetes rate. Plan from CDC national 12% plus your panel.
• A city of 500k–1M usually means mixed payer mix: Medicare FFS under JF, Medicare Advantage, workers’ comp, and cash-pay sports medicine. One SKU list rarely serves all four without a utilization policy.

Payer geography for Seattle, WA

JF reviewers still want serial wound measurements and conservative-care history before CTPs, whether diabetes in Seattle is 6.1% or not. PLACES is planning data. The LCD is the claim.

How we’d stand this up in clinic